Voltin, Conrad-Amadeus http://orcid.org/0000-0002-5437-3959
Paccagnella, Andrea
Winkelmann, Michael
Heger, Jan-Michel
Casadei, Beatrice
Beckmann, Laura
Herrmann, Ken
Dekorsy, Franziska J.
Kutsch, Nadine
Borchmann, Peter
Fanti, Stefano
Kunz, Wolfgang G.
Subklewe, Marion
Kobe, Carsten
Zinzani, Pier Luigi
Stelljes, Matthias
Roth, Katrin S.
Drzezga, Alexander
Noppeney, Richard
Rahbar, Kambiz
Reinhardt, H. Christian
von Tresckow, Bastian
Seifert, Robert
Albring, Jörn C.
Blumenberg, Viktoria
Farolfi, Andrea
Flossdorf, Sarah
Gödel, Philipp
Hanoun, Christine
Funding for this research was provided by:
German Research Foundation (451580403)
Bavarian Elite Graduate Training Network
Wilhelm Sander Foundation (2018.087.1)
Else Kröner-Fresenius Foundation
German Cancer Consortium
Bavarian Center for Cancer Research
Universitätsklinikum Köln
Article History
Received: 15 July 2023
Accepted: 30 November 2023
First Online: 20 December 2023
Declarations
:
: This retrospective study was conducted after obtaining institutional ethics committee approvals.
: Written informed consent was obtained from all patients prior to enrollment in this study.
: JMH: Miltenyi Biotec—advisory role; Incyte, Novartis—research funding; Gilead Pharmaceuticals, Novartis—travel support. NK: AstraZeneca, Roche—paid honoraria; AstraZeneca, Gilead Sciences, Inc.—research funding; AbbVie, AstraZeneca, Gilead Sciences, Inc., Janssen, Celgene—travel support. PB: Bristol Myers Squibb, Celgene, Gilead Sciences, Janssen, Miltenyi Biotec, Novartis—paid honoraria. MS: AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Miltenyi Biotec, Molecular Partners, Novartis, Pfizer, Takeda—consultant role; Amgen, AstraZeneca, Celgene, Gilead Sciences, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Takeda—lectureship honoraria; Amgen, Celgene, Gilead Sciences, Janssen, Miltenyi Biotec, Novartis, Roche, Seattle Genetics, Takeda—research funding. PLZ: ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Celltrion Healthcare, EUSA Pharma, Gilead Sciences, Incyte, Janssen-Cilag, Kyowa Kirin, Merck Sharp & Dohme, Novartis, Roche, Sandoz, Secura Bio, Servier, Takeda—advisory role; EUSA Pharma, Merck Sharp & Dohme, Novartis—consultant role; AstraZeneca, BeiGene, Bristol Myers Squibb, Celltrion Healthcare, EUSA Pharma, Gilead Sciences, Incyte, Janssen-Cilag, Kyowa Kirin, Merck Sharp & Dohme, Novartis, Roche, Servier, Takeda—lectureship honoraria. AD: Bayer Vital GmbH, Biogen, GE Healthcare, Invicro, Novartis, Novo Nordisk, Sanofi, Siemens Healthineers—lectureship honoraria or advisory role; <sup>18</sup>F-JK–prostate-specific membrane antigen–7, 2-alkoxy-6-<sup>18</sup>F-fluoronicotinoyl-substituted Lys-C(O)-Glu derivatives—patent holder; Avid Radiopharmaceuticals, Inc., Eisai, GE Healthcare, Life Molecular Imaging, Novartis, Siemens Healthineers, SOFIE—research funding; Lantheus Holdings, Inc., Siemens Healthineers AG—stockholder. KR: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Janssen-Cilag, Sirtex Medical—paid honoraria; ABX advanced biochemical compounds GmbH, ABX-CRO, Advanced Accelerator Applications, Bayer—consultant or advisory role. HCR: CDL Therapeutics GmbH—co-founder; AbbVie, AstraZeneca, Bristol Myers Squibb, Merck, Noscendo GmbH, Novartis, Roche, Vertex Pharmaceuticals—consultant role and lectureship honoraria; AstraZeneca, Gilead Pharmaceuticals—research funding. BvT: Allogene Therapeutics, Amgen, Bristol Myers Squibb, Cerus Corporation, Gilead Sciences, Incyte, IQVIA, Merck Sharp & Dohme, Miltenyi Biotec, Noscendo GmbH, Novartis, PentixaPharm GmbH, Roche, Pfizer, Takeda—consultant or advisory role; AstraZeneca, Bristol Myers Squibb, Incyte, Merck Sharp & Dohme, Novartis, Roche Pharma AG, Takeda—paid honoraria; Merck Sharp & Dohme, Novartis, Takeda—research funding; AbbVie, AstraZeneca, Gilead Sciences, Merck Sharp & Dohme, Novartis, Roche, Takeda—travel support. RS: Boehringer Ingelheim Fonds, Else Kröner-Fresenius Foundation—research funding. VB: Gilead Sciences, Roche—consultant role; Gilead Sciences, Janssen, Novartis—paid honoraria; Bristol Myers Squibb, Gilead Sciences, Janssen, Novartis, Roche, Takeda—research funding. PG: Gilead Sciences, Novartis—travel support. CH: AstraZeneca, Bristol Myers Squibb, Janssen, Takeda—paid honoraria; AbbVie, Janssen—travel support.